Compare · NTRA vs OSCR
NTRA vs OSCR
Side-by-side comparison of Natera Inc. (NTRA) and Oscar Health Inc. (OSCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and OSCR operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $27.81B, about 5.2x OSCR ($5.40B).
- Over the past year, NTRA is up 33.3% and OSCR is up 38.4% - OSCR leads by 5.0 points.
- NTRA has been more active in the news (24 items in the past 4 weeks vs 12 for OSCR).
- Both have 25 recent analyst ratings on file.
- Company
- Natera Inc.
- Oscar Health Inc.
- Price
- $201.31+3.31%
- $17.96+0.11%
- Market cap
- $27.81B
- $5.40B
- 1M return
- +0.65%
- +56.58%
- 1Y return
- +33.34%
- +38.37%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- 2021
- News (4w)
- 24
- 12
- Recent ratings
- 25
- 25
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Oscar Health Inc.
Oscar Health, Inc. provides health insurance products and services in the United States. The company offers Individual & Family, Small Group, and Medicare Advantage plans, as well as +Oscar, a full stack technology platform. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was founded in 2012 and is headquartered in New York, New York.
Latest NTRA
- Natera to Report its First Quarter Results on May 7, 2026
- CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold $1,001,645 worth of shares (5,063 units at $197.84) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 58,291 units (SEC Form 4) (withholding obligation)
- CEO AND PRESIDENT Chapman Steven Leonard sold $1,191,775 worth of shares (5,838 units at $204.14) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 150,769 units (SEC Form 4) to satisfy tax liability
- CO-FOUNDER Sheena Jonathan sold $699,693 worth of shares (3,544 units at $197.43) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 255,711 units (SEC Form 4) (withholding obligation)
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $379,811 worth of shares (1,861 units at $204.09) as part of a pre-agreed trading plan, decreasing direct ownership by 0.83% to 223,024 units (SEC Form 4) (tax liability)
- PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $344,517 worth of shares (1,688 units at $204.10) as part of a pre-agreed trading plan, decreasing direct ownership by 0.89% to 187,511 units (SEC Form 4) to cover taxes
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $445,341 worth of shares (2,182 units at $204.10) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 145,700 units (SEC Form 4) (withholding tax)
- Director Marcus Gail Boxer was granted 330 shares, increasing direct ownership by 6% to 6,183 units (SEC Form 4)
- Director Baynes Roy D. was granted 83 shares, increasing direct ownership by 0.45% to 18,512 units (SEC Form 4)
- Director Bertagnolli Monica was granted 83 shares, increasing direct ownership by 2% to 5,374 units (SEC Form 4)
Latest OSCR
- SEC Form DEFA14A filed by Oscar Health Inc.
- SEC Form DEF 14A filed by Oscar Health Inc.
- Oscar Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Oscar Health, Inc. Appoints Director Siddhartha Sankaran as Independent Chair of the Board
- Oscar Health upgraded by Jefferies with a new price target
- Meet Lucie. A New Way to Shop for Healthcare.
- SEC Form 4 filed by Sankaran Sid
- SEC Form 4 filed by Gassen William
- SEC Form 4 filed by Boyd Jeffery H
- SEC Form 4 filed by Plouffe David